Recently, glucocorticoid receptor (GR) has been identified to reactivate the AR transcriptome in the absence of AR in patients resistant to enzalutamide1, an anti-androgen drug, suggesting that mutual exclusivity, which broadly characterizes cancer-driving aberrations in signalling pathways5, also dictates driver TFs that reactivate the AR transcriptome in CRPC. The gene discussed is NR3C1; the disease is cancer.